Neoadjuvant Listeria or Daratumumab in Prostate Cancer

Summary

The goal of this clinical research study is to learn about biomarker changes in patients who have primary prostate cancer after receiving Darzalex (daratumumab) and then have a prostatectomy (the surgical removal of the prostate) as part of their standard care. Biomarkers are found in the blood/tissue and may be related to your reaction to the study drug.

Timeline

Start

2017-03-01

Primary completion

2019-03-01

Completion

2019-03-01

Outcome

Outcome not reported

Stopped: “PI's Request”

Drugs

Indications